Real-World Outcomes of Combined Goniotomy and Canaloplasty Using the Streamline Surgical System Authors: Taylor N Drake, Kush Shah, Siddharth Bhargava, Constance O Okeke Published: 2026 ABSTRACT PurposeTo evaluate real-world outcomes of combined goniotomy and canaloplasty, performed with the Streamline Surgical System, on intraocular pressure (IOP) and medication burden in patients with ocular hypertension and open-angle glaucoma in a US-based clinical practice.Patients and MethodsThis retrospective, single-center chart review included patients who underwent the Streamline procedure either as standalone or in combination with cataract surgery between January 2022 and December 2023. Outcome measures included change in mean IOP and number of IOP-lowering medications from baseline through 12 months, analyzed in the overall cohort, with exploratory subgroup analyses stratified by race and glaucoma severity (mild, moderate, severe).ResultsA total of 132 eyes (132 patients, 54.5% African-American) were included. The Streamline procedure was performed in combination with cataract surgery in 119 eyes and as a standalone procedure in 13 eyes. Mean IOP decreased significantly from 17.1±5.8 mmHg at baseline to 13.2±4.1 mmHg at 12 months (p<0.001), and the mean number of IOP-lowering medications decreased from 1.6±1.3 to 1.2±1.5 (p<0.001). When stratified by race, no consistent differences in mean IOP or medication use were observed between African-American and Caucasian patients across postoperative visits, except at the 3-month time point. Reductions in mean IOP were observed across all glaucoma severity subgroups; however, statistical significance was achieved only in the mild and moderate subgroups. Reductions in medication burden were observed in the mild and moderate subgroups, with statistical significance only in the mild subgroup. Interpretation of these findings is limited by the retrospective design and the predominance of combined cataract procedures, which precludes isolation of the independent effect of the Streamline procedure.ConclusionStreamline goniotomy with canaloplasty was associated with significant reductions in mean IOP and medication burden through 12 months in a real-world clinical cohort. Introduction Glaucoma and cataract are leading causes of visual impairment worldwide, and their coexistence is increasingly common in the aging population.1 Approximately 25 to 50% of glaucoma patients do not achieve adequate intraocular pressure (IOP) control with medical therapy alone, necessitating surgical intervention.2 Traditionally, such cases were managed with invasive procedures such as trabeculectomy or tube shunt implantation. Although effective, these procedures are associated with significant postoperative risks and long-term complications.3 Minimally invasive glaucoma surgery (MIGS) procedures were developed to address the limitations of medical management and risks associated with traditional glaucoma filtration surgery.4 Due to their favorable safety profile, MIGS procedures allow for earlier surgical intervention and may be performed as standalone procedures or in combination with cataract surgery. Among MIGS options, trabecular meshwork and Schlemm’s canal-based procedures are generally considered to have the most favorable safety profiles.5 Canaloplasty is a minimally invasive, nonpenetrating procedure intended to restore the natural aqueous outflow system through microcatheterization and viscodilation of Schlemm’s canal. The procedure targets multiple sites of outflow resistance by improving trabecular meshwork function, dilating Schlemm’s canal, and enhancing distal collector channel patency.4,6 It has a well-documented safety and efficacy profile in reducing IOP.7–10 The Streamline Surgical System (New World Medical, Rancho Cucamonga, CA) is an ab interno microinvasive glaucoma surgery device that facilitates focal trabecular meshwork access through microgoniotomies to deliver an ophthalmic viscosurgical device (OVD) into Schlemm’s canal, thereby viscodilating the canal and distal outflow pathways without implant placement. The delivery of OVD across several clock hours improves aqueous outflow. Prior studies evaluating the Streamline Surgical System have demonstrated reductions in IOP and medication burden; however, most did not perform goniotomy (only one study performed goniotomy extending across 1–2 clock hours).11 Furthermore, these reports were limited by relatively small sample sizes.11–17 Comparative evidence with other MIGS procedures remains limited. Also, despite the disproportionate burden of open-angle glaucoma among African-American patients, most published studies of Streamline outcomes (and of canaloplasty outcomes more broadly) have underenrolled African-American patients relative to their share of the overall population.11,12,18–21 Mbagwu et al have reported significant IOP lowering from 365° canaloplasty in African-American patients in a large registry study.22 Lazcano et al have reported on results for Hispanic adults undergoing Streamline; no such reporting exists for African-American patients.15 The present study is part of the Advocates for Glaucoma Education (AGE) Initiative, which aims to provide real-world perspectives and outcomes of the Streamline procedure for IOP reduction and to decrease the risk of progressive glaucomatous damage within a large, US-based clinical practice population. Real-world outcome data are particularly valuable in evaluating MIGS procedures, as patient populations, surgical decision-making, and postoperative management often differ from those in controlled clinical trial environments. Evaluating outcomes in routine clinical practice may therefore provide important insights into procedure performance across a broader, more diverse patient population. Materials and Methods This retrospective study reviewed chart records of patients who underwent the Streamline procedure performed by a single experienced glaucoma surgeon (COO) between January 2022 and December 2023 at Virginia Eye Consultants, an EyeCare Partners practice in Norfolk, VA, USA. The study was performed in accordance with the tenets of the Declaration of Helsinki and its amendments and was approved by the Institutional Review Board of Eastern Virginia Medical School (ID: 22–05-EX-0103), with waiver of informed consent as data were collected as part of routine clinical care and analyzed in a de-identified manner. Inclusion and Exclusion Criteria Patients aged ≥18 years with a diagnosis of primary or secondary open-angle glaucoma, ocular hypertension, chronic angle-closure glaucoma, or mixed-mechanism glaucoma who underwent the Streamline procedure, either as a standalone procedure or in combination with cataract surgery, were eligible for inclusion. Glaucoma diagnosis was established by an experienced glaucoma specialist based on optical coherence tomography retinal nerve fiber layer (OCT-RNFL) analysis, standard automated perimetry, dilated fundus examination, and gonioscopy. Glaucoma severity was categorized as mild, moderate, or severe based on clinical assessment, using ICD-10 codes with visual field findings determining the severity. Exclusion criteria included acute angle-closure glaucoma or having undergone any concurrent glaucoma intervention other than the Streamline procedure at the time of surgery. Eyes with less than one month of postoperative follow-up were also excluded. Study Procedure All eyes underwent combined goniotomy and canaloplasty with the Streamline Surgical System using ab interno access to Schlemm’s canal under direct gonioscopic visualization. In accordance with established definitions of canaloplasty and goniotomy, treatment was performed over approximately 3 to 4 clock hours to achieve both viscodilation of Schlemm’s canal and opening of the trabecular meshwork. The Streamline Surgical System was advanced toward the trabecular meshwork, and the device tip was sequentially engaged through the trabecular meshwork to deliver OVD into Schlemm’s canal. The device was translated circumferentially to the left and/or right to create sequential goniotomies, resulting in a goniotomy cleft spanning approximately 3 to 4 clock hours in the nasal quadrant. In cases where the goniotomies were not fully contiguous, a Sinskey hook was used to connect and complete the goniotomy cleft over the intended 3 to 4 clock hours. This was followed by additional viscoelastic injection using a 30-gauge cannula to enhance visualization of the goniotomy cleft and to assess the posterior wall of Schlemm’s canal. The Streamline procedure could be performed either as a standalone procedure or combined with cataract surgery. Standalone Streamline treatment was selected when concurrent cataract extraction was not indicated. Combined Streamline and cataract surgery was performed when cataract extraction was independently indicated. For combined procedures, the Streamline procedure was performed after cataract surgery and intraocular lens (IOL) implantation. Procedure selection was individualized based on glaucoma severity, current and target IOP, medication burden, angle anatomy, cataract status, prior treatment, overall risk profile, and shared clinical decision-making after discussing alternatives, including incisional glaucoma surgeries, with the patients. Outcome measures included the change in mean IOP, the percentage change in IOP, and the change in the number of IOP-lowering medications from baseline through 12 months postoperatively. Outcomes were also analyzed after stratifying eyes by race and by glaucoma severity (mild, moderate, severe). Statistical Analysis No a priori sample-size calculation was performed because this retrospective study included all eligible eyes identified during the prespecified study period. Data analysis was performed using SPSS software (version 27.0) for Windows (IBM SPSS Statistics 27, IBM Inc., Armonk, NY). No data imputations were performed for the missing data, and analyses were performed on the available data at each postoperative visit. For continuous variables, data normality was assessed using the Kolmogorov–Smirnov test. Depending on the data distribution, repeated-measures ANOVA or Friedman tests were used to assess whether any statistically significant differences in IOP and the number of IOP-lowering medications exist across different time periods (Month 3 to Month 12) from baseline. A p-value <0.05 was considered statistically significant. If the ANOVA or Friedman test results were found to be significant (p<0.05), subsequent paired t-tests or Wilcoxon signed-rank tests were used to test for differences between time periods. P-values were adjusted for multiple testing, and a value <0.0167 was considered statistically significant. For between-group differences, depending on the data distribution, an Independent t-test or non-parametric Mann–Whitney U-test was employed to check for significant differences in IOP and the number of IOP-lowering medications between the African-American and Caucasian patients at baseline and different postoperative time points through 12 months. A p-value <0.05 was considered statistically significant. Results This retrospective analysis included 132 eyes of 132 patients. The mean age of the study population was 68.9 ± 8.6 years. African-American patients comprised 54.5% (72/132) of the study population. The Streamline procedure was performed in combination with cataract surgery in 119 eyes (90.2%) and as a standalone procedure in 13 eyes (9.8%). Patient demographic and baseline characteristics are listed in Table 1.Table 1Demographics and Glaucoma Status at Baseline in the Overall CohortN (eyes)132Age (years) (Mean ± SD)68.9 ± 8.6Procedure, n (%) Streamline goniotomy + canaloplasty + cataract surgery119 (90.2%) Standalone Streamline goniotomy + canaloplasty13 (9.8%)Sex, n (%) Male63 (47.7%) Female69 (52.3%)Ethnicity, n (%) African-American72 (54.5%) Caucasian53 (40.2%) Other7 (5.3%)Glaucoma Diagnosis, n (%) Ocular hypertension4 (3.0%) Mild open-angle glaucoma85 (64.4%) Moderate open-angle glaucoma20 (15.2%) Severe open-angle glaucoma23 (17.4%)Abbreviation: SD, Standard Deviation. Table 1Demographics and Glaucoma Status at Baseline in the Overall CohortN (eyes)132Age (years) (Mean ± SD)68.9 ± 8.6Procedure, n (%) Streamline goniotomy + canaloplasty + cataract surgery119 (90.2%) Standalone Streamline goniotomy + canaloplasty13 (9.8%)Sex, n (%) Male63 (47.7%) Female69 (52.3%)Ethnicity, n (%) African-American72 (54.5%) Caucasian53 (40.2%) Other7 (5.3%)Glaucoma Diagnosis, n (%) Ocular hypertension4 (3.0%) Mild open-angle glaucoma85 (64.4%) Moderate open-angle glaucoma20 (15.2%) Severe open-angle glaucoma23 (17.4%)Abbreviation: SD, Standard Deviation. Demographics and Glaucoma Status at Baseline in the Overall Cohort Abbreviation: SD, Standard Deviation. Of the 132 eyes included at baseline, 78 eyes had evaluable data at postoperative 12 months. Figure 1 illustrates the mean IOP and percentage change in IOP at different time points for the overall cohort. At 12 months postoperatively, mean IOP decreased by 22.5% from baseline, a difference that was statistically significant (p <0.001). Figure 1Mean IOP at baseline, with mean IOP and percentage change in IOP (ΔIOP%, from baseline) at each postoperative visit for the overall cohort. * represents a statistically significant difference from baseline.A graph with error bars and a data table shows Mean IOP and delta IOP percentage over follow-up (FU) time. Legend: Mean IOP and delta IOP percent. Horizontal axis: FU Time with categories: Pre Op, 1 Day (1 D), 1 Week (1 W), 1 Month (1 M), 3 Months (3 M), 6 Months (6 M), 12 Months (12 M). Left vertical axis: Mean IOP (0 to 30). Mean IOP values: Pre Op: 17.1; 1 D: 13.0; 1 W: 16.0; 1 M: 14.9; 3 M: 13.4; 6 M: 14.1; 12 M: 13.2. Right vertical axis: delta IOP percent (negative 30 percent to 30 percent). Delta IOP percent values: 1 D: negative 23.8 percent; 1 W: negative 6.6 percent; 1 M: negative 12.6 percent; 3 M: negative 21.6 percent; 6 M: negative 17.5 percent; 12 M: negative 22.5 percent. Table by FU Time. Row n: Pre Op: 132; 1 D: 132; 1 W: 132; 1 M: 132; 3 M: 113; 6 M: 85; 12 M: 78. Mean medication plus minus SD: Pre Op: 1.6 plus minus 1.3; 1 D: 0.9 plus minus 1.1; 1 W: 0.9 plus minus 1.1; 1 M: 1.0 plus minus 1.2; 3 M: 1.0 plus minus 1.3; 6 M: 1.3 plus minus 1.3; 12 M: 1.2 plus minus 1.5. Change in medication (Mean Med plus minus SD): 1 D: negative 0.7 plus minus 1.0; 1 W: negative 0.7 plus minus 1.0; 1 M: negative 0.6 plus minus 1.0; 3 M: negative 0.7 plus minus 0.9; 6 M: negative 0.5 plus minus 0.9; 12 M: negative0.5 plus minus 1.0.Bar-line graph of mean and delta intraocular pressure percentage over time. Mean IOP at baseline, with mean IOP and percentage change in IOP (ΔIOP%, from baseline) at each postoperative visit for the overall cohort. * represents a statistically significant difference from baseline. Figure 2 depicts the mean number of IOP-lowering medications at baseline and at postoperative follow-up intervals. A statistically significant reduction in the mean number of IOP-lowering medications was observed from baseline through 12 months (p <0.001). At 12 months postoperatively, 44.9% (35/78) of eyes were medication-free, compared to 16.7% (22/132) of eyes at baseline. Figure 2Mean number of IOP-lowering medications at baseline and at each postoperative follow-up visit for the overall cohort. * represents a statistically significant difference from baseline.A bar graph showing the mean number of IOP-lowering medications across follow-up time points. Mean number of IOP-lowering medications at baseline and at each postoperative follow-up visit for the overall cohort. * represents a statistically significant difference from baseline. Subgroup Analyses Outcomes were further evaluated after stratification by race (Table 2). African-American patients presented with more advanced glaucoma at baseline (mean deviation: −8.6 ± 10.7 dB in African-American patients vs −4.4 ± 6.9 dB in Caucasian patients) and required a greater number of IOP-lowering medications at baseline compared with Caucasian patients. Postoperatively, mean IOP and medication use followed similar trends between groups, with no consistent differences observed across follow-up visits except at the 3-month time point. Percentage reductions in IOP over time were comparable between racial subgroups.Table 2Mean IOP and Mean Number of IOP-Lowering Medications Over Time, Stratified by RacePreoperative1 Day1 Week1 Month3 Months6 Months12 MonthsN72727272655546Mean Intraocular Pressure (IOP) (mmHg)African-American17.113.116.015.114.014.513.5Caucasian17.213.016.514.812.513.813.0Mean Number of IOP-lowering MedicationsAfrican-American1.9*1.01.01.21.3*1.51.5Caucasian1.2*0.80.80.80.7*1.31.1Notes: *p-value <0.05 represents a statistically significant difference between the two groups for a given time point. Table 2Mean IOP and Mean Number of IOP-Lowering Medications Over Time, Stratified by RacePreoperative1 Day1 Week1 Month3 Months6 Months12 MonthsN72727272655546Mean Intraocular Pressure (IOP) (mmHg)African-American17.113.116.015.114.014.513.5Caucasian17.213.016.514.812.513.813.0Mean Number of IOP-lowering MedicationsAfrican-American1.9*1.01.01.21.3*1.51.5Caucasian1.2*0.80.80.80.7*1.31.1Notes: *p-value <0.05 represents a statistically significant difference between the two groups for a given time point. Mean IOP and Mean Number of IOP-Lowering Medications Over Time, Stratified by Race Notes: *p-value <0.05 represents a statistically significant difference between the two groups for a given time point. Changes in IOP and medication burden were analyzed after stratifying eyes by glaucoma severity (mild, moderate, severe). There were only 4 patients with ocular hypertension; these patients were not included in the severity subgroup analyses. As shown in Table 3, mean IOP decreased significantly from baseline to 12 months in the mild and moderate glaucoma subgroups. A statistically significant reduction in medication burden was observed only in the mild glaucoma subgroup.Table 3Mean IOP and Mean Number of IOP-Lowering Medications Over Time, Stratified by Baseline Glaucoma SeverityPreoperative1 Day1 Week1 Month3 Months6 Months12 MonthsMild n85858585715451 Intraocular Pressure (IOP) Mean17.212.716.615.413.7*14.4*13.5* % change from baseline(−26.2%)(−3.5%)(−10.3%)(−20.5%)(−16.6%)(−21.5%) Number of Medications Mean1.30.60.50.70.6*1.0*0.7* % patients on zero medications20.0%65.9%71.8%67.1%71.8%55.6%56.9% % patients requiring ≥3 medications16.5%5.9%4.7%8.2%7.0%9.3%3.9%Moderate n20202020181615 Intraocular Pressure (IOP) Mean16.012.613.713.712.7*13.0*11.7* % change from baseline(−21.0%)(−14.1%)(−14.4%)(−20.2%)(−18.5%)(−26.4%) Number of Medications Mean2.31.61.71.71.92.01.9 % patients on zero medications5.0%25.0%15.0%25.0%11.1%6.3%20.0% % patients requiring ≥3 medications50.0%15.0%25.0%30.0%27.8%25.0%26.7%Severe n23232323211412 Intraocular Pressure (IOP) Mean17.314.815.914.612.7*14.6*14.0 % change from baseline(−14.5%)(−8.5%)(−16.0%)(−27.0%)(−16.0%)(−19.3%) Number of Medications Mean2.51.71.71.71.7*2.12.7 % patients on zero medications4.3%13.0%13.0%8.7%19.0%7.1%25.0% % patients requiring ≥3 medications56.5%13.0%17.4%13.0%19.0%42.9%58.3%Notes: *p <0.0167, representing a statistically significant difference from baseline. Table 3Mean IOP and Mean Number of IOP-Lowering Medications Over Time, Stratified by Baseline Glaucoma SeverityPreoperative1 Day1 Week1 Month3 Months6 Months12 MonthsMild n85858585715451 Intraocular Pressure (IOP) Mean17.212.716.615.413.7*14.4*13.5* % change from baseline(−26.2%)(−3.5%)(−10.3%)(−20.5%)(−16.6%)(−21.5%) Number of Medications Mean1.30.60.50.70.6*1.0*0.7* % patients on zero medications20.0%65.9%71.8%67.1%71.8%55.6%56.9% % patients requiring ≥3 medications16.5%5.9%4.7%8.2%7.0%9.3%3.9%Moderate n20202020181615 Intraocular Pressure (IOP) Mean16.012.613.713.712.7*13.0*11.7* % change from baseline(−21.0%)(−14.1%)(−14.4%)(−20.2%)(−18.5%)(−26.4%) Number of Medications Mean2.31.61.71.71.92.01.9 % patients on zero medications5.0%25.0%15.0%25.0%11.1%6.3%20.0% % patients requiring ≥3 medications50.0%15.0%25.0%30.0%27.8%25.0%26.7%Severe n23232323211412 Intraocular Pressure (IOP) Mean17.314.815.914.612.7*14.6*14.0 % change from baseline(−14.5%)(−8.5%)(−16.0%)(−27.0%)(−16.0%)(−19.3%) Number of Medications Mean2.51.71.71.71.7*2.12.7 % patients on zero medications4.3%13.0%13.0%8.7%19.0%7.1%25.0% % patients requiring ≥3 medications56.5%13.0%17.4%13.0%19.0%42.9%58.3%Notes: *p <0.0167, representing a statistically significant difference from baseline. Mean IOP and Mean Number of IOP-Lowering Medications Over Time, Stratified by Baseline Glaucoma Severity Notes: *p <0.0167, representing a statistically significant difference from baseline. Eyes undergoing the standalone Streamline procedure demonstrated higher baseline IOP and medication burden compared with combined cases. Postoperative IOP reductions appeared similar; however, formal statistical comparisons were not performed due to unequal sample sizes. Safety The procedure was generally well tolerated. No sight-threatening intraoperative or postoperative complications attributable to the Streamline procedure were observed during the study period. The most commonly observed postoperative events included transient IOP elevation, mild postoperative inflammation, and limited blood reflux or bleeding observed on gonioscopy, all of which resolved with standard postoperative management. No cases required additional surgical intervention related to these events. One posterior capsule rupture occurred during combined cataract surgery and was determined to be unrelated to the Streamline procedure or device. A summary of observed adverse events is provided in Table 4. No secondary glaucoma procedures were required during the follow-up period.Table 4Ocular Adverse EventsAdverse Events (AEs)n/N (%)Elevated intraocular pressure (IOP)49/132 (37.1%)Rebound/prolonged inflammation41/132 (31.1%)Bleeding/heme on gonioscopy (source not clear)4/132 (3.03%)Persistent fluid/hemorrhages1/132 (0.76%)Acute follicular conjunctivitis1/132 (0.76%)Transient reduction in vision1/132 (0.76%) Table 4Ocular Adverse EventsAdverse Events (AEs)n/N (%)Elevated intraocular pressure (IOP)49/132 (37.1%)Rebound/prolonged inflammation41/132 (31.1%)Bleeding/heme on gonioscopy (source not clear)4/132 (3.03%)Persistent fluid/hemorrhages1/132 (0.76%)Acute follicular conjunctivitis1/132 (0.76%)Transient reduction in vision1/132 (0.76%) Ocular Adverse Events Discussion The Streamline Surgical System is an ab interno microinvasive glaucoma surgery device that facilitates canaloplasty through viscodilation of Schlemm’s canal, as well as goniotomy, through focal incision of the trabecular meshwork, typically performed over multiple clock hours of the conventional outflow pathway under direct gonioscopic visualization. The present study evaluated 12-month outcomes of combined goniotomy and canaloplasty with Streamline in a real-world clinical setting, including patients with mild to severe glaucoma who underwent the procedure either as a standalone intervention or in combination with cataract surgery. From baseline to 12 months postoperatively, a statistically significant 22.5% reduction in mean IOP and a significant reduction in medication burden were observed. More than 40% of the eyes achieved an IOP reduction of 20% or more from baseline to 12 months, and 45% were medication-free at final follow-up. A substantial proportion of patients in this cohort were African-American, a population known to experience a higher prevalence and more aggressive progression of open-angle glaucoma. Prior literature has reported potential disparities in glaucoma surgical outcomes,13,23 making evaluation of real-world MIGS outcomes across racial groups clinically relevant. In the present study, reductions in IOP were observed in both African-American and Caucasian patients, with postoperative trends appearing generally similar between groups. Although African-American patients required a greater number of medications at baseline, postoperative medication use and IOP reduction followed comparable trajectories over time. These findings should be interpreted cautiously given the retrospective design and absence of statistical power for subgroup comparisons but suggest that the Streamline procedure performs consistently across diverse patient populations. Patients with severe glaucoma were also included in the present study as part of routine clinical practice. These selected patients had stable disease at or near their individualized target IOP, and the goal of the combined goniotomy and canaloplasty procedure was to maintain pressure control, reduce medications, and/or leverage the opportunity presented by concurrent cataract surgery to optimize long-term IOP management. Although all severity subgroups demonstrated reductions in mean IOP, statistical significance was reached only in the mild and moderate subgroups. Reductions in medication burden were most pronounced in the mild glaucoma subgroup, with more modest reductions observed in the moderate subgroup. More than half (57%) of mild glaucoma patients and 20% of the moderate glaucoma patients required zero medications at 12 months. The mild group also showed more than 75% reduction from baseline in the proportion of patients requiring 3 or more medications at postoperative 12 months. The corresponding reduction in the moderate subgroup was almost 50%. In the severe glaucoma subgroup, mean medication use remained relatively stable through 12 months, although a subset (25%) of eyes achieved medication independence at final follow-up. These findings suggest that combined goniotomy and canaloplasty with Streamline may provide meaningful IOP reduction across a spectrum of glaucoma severities, with particular benefit in reducing medication burden in patients with milder disease. Previously published studies evaluating the outcomes of goniotomy alone or canaloplasty with trabeculotomy across the full spectrum of glaucoma severity, including advanced cases, also reported good glaucoma control with these procedures.24–26 These findings support a potential role for angle-based procedures in appropriately selected patients with advanced glaucoma, particularly when individualized treatment goals include maintaining IOP control, reducing medication burden, or deferring more invasive filtration surgery after shared decision-making. Several prior studies have reported reductions in IOP and medication burden following the Streamline procedure;11–17 however, the present study represents the largest reported cohort to date and includes a significantly higher proportion of African-American patients, a demographic group that is more susceptible to open-angle glaucoma and glaucoma progression.27–31 While a direct comparison of the present study results with those reported previously is limited due to differences in patient populations and baseline characteristics, the magnitude of IOP reduction observed in the present study (4 mmHg) appears greater than that reported in several previously published series, although direct comparison is limited by differences in study populations and methodology.11–13,15,17 In the present study, combined goniotomy (3–4 clock hours) and canaloplasty was performed with the Streamline Surgical System. In contrast, most previously published studies performed canaloplasty alone,12,13,15,16 and one performed a smaller goniotomy (1–2 clock hours).11 Differences in surgical technique, including treatment over a broader arc of the trabecular meshwork, may partially explain the greater magnitude of IOP reduction observed in this cohort compared with that reported in previously published studies. The Streamline procedure occupies a unique position within the evolution of angle-based surgery because it can potentially address both proximal and distal components of conventional aqueous outflow resistance. It is known from published studies of excisional or ablative goniotomy procedures such as the Kahook Dual Blade (KDB) or Trabectome that removing or ablating a strip of the trabecular meshwork can result in meaningful reductions in IOP and medication burden.32 However, unlike isolated goniotomy, the Streamline surgical procedure combines a highly targeted trabecular goniotomy with focal delivery of viscoelastic into Schlemm’s canal, thereby adding a canaloplasty component intended to address resistance beyond the trabecular meshwork. Efficacy has also been reported with circumferential 360° canaloplasty with trabeculotomies of up to 180°.24,33 Unlike these procedures, however, Streamline treats the visible nasal angle with focal goniotomies and focal viscodilation, typically over approximately 3–4 clock hours, as in the present study. Direct comparison of the present study results with the published literature on goniotomy alone or with 360° circumferential canaloplasty procedures cannot be made due to differences in study designs, study populations, baseline characteristics, extent of angle treatment, and whether surgery was combined with phacoemulsification or performed as a standalone procedure. The mean reduction in the number of IOP-lowering medications in the present study was somewhat smaller than that reported in prior Streamline studies.11–13,15,16 The more modest reduction in medication burden compared with previous studies likely reflects multiple factors, including individualized target IOPs, continued adjunctive therapy in higher-risk eyes, and variation in real-world postoperative management. In addition, 16.7% of eyes were medication-free at baseline, creating a potential floor effect that limited the opportunity for further medication reduction. Because canaloplasty restores physiologic aqueous outflow without permanent implant placement, implant-related risks such as endothelial cell loss may be minimized.17 A previous study demonstrated that endothelial cell loss following the Streamline procedure combined with phacoemulsification (16.8% at 12 months),13 is consistent with the endothelial cell loss reported following phacoemulsification alone in glaucomatous eyes (~10–17% in various studies).34 As the risk of endothelial cell loss following the Streamline Surgical System is no greater than that of phacoemulsification alone,13,15,34 the procedure is commonly combined with cataract surgery, as was done in 90.2% of the patients in the present study. The present real-world study is limited by its retrospective study design. Owing to the study’s retrospective nature, treatment selection reflected routine clinical decision-making rather than random assignment, and unmeasured factors may have influenced both procedure selection and postoperative outcomes. Because most procedures were combined with cataract surgery, the independent contribution of the Streamline procedure to IOP reduction cannot be fully isolated. Cataract extraction itself may reduce IOP, and the absence of a contemporaneous phacoemulsification-only control group limits attribution of the observed treatment effect solely to Streamline. Future comparative studies involving a control group of patients undergoing cataract surgery alone may provide more insight into the IOP reduction caused by the Streamline procedure alone. Longer-term follow-up studies are needed to assess durability of IOP reduction over time. An ongoing randomized controlled trial comparing the Streamline procedure with iStent W has shown similar outcomes with the two procedures.16 Nevertheless, further studies comparing the efficacy of the Streamline procedure with other available MIGS procedures are warranted. Although all procedures were performed by a single surgeon, thereby reducing variability in surgical technique and postoperative management, this may also limit generalizability. Additionally, subgroup analyses by race and procedure type were exploratory and not powered for definitive comparative conclusions. Only 13 subjects in the present study underwent Streamline alone. Therefore, due to unequal sample size distribution in the two groups (Streamline alone vs Streamline plus cataract surgery), formal between-group comparisons were not made, and data for the overall cohort were presented. Future studies with a larger dataset are required to evaluate the IOP and medication reduction efficacy of Streamline alone vs Streamline combined with cataract surgery. Conclusion In this retrospective, real-world cohort, combined goniotomy and canaloplasty with Streamline was associated with reductions in IOP and medication burden through 12 months. Interpretation is limited by the predominance of combined cataract procedures, incomplete follow-up, the single-surgeon design, and the exploratory nature of the subgroup analyses. Prospective, controlled, multicenter studies with longer follow-up are needed to confirm these findings and better distinguish the independent contribution of the Streamline procedure from cataract surgery.